Stocks and Investing
Stocks and Investing
Tue, March 21, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Mon, March 20, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Gregory Renza Reiterated (SPRB) at Buy and Held Target at $8 on, Mar 20th, 2023
Gregory Renza of RBC Capital, Reiterated "Spruce Biosciences, Inc." (SPRB) at Buy and Held Target at $8 on, Mar 20th, 2023.
Gregory has made no other calls on SPRB in the last 4 months.
There are 2 other peers that have a rating on SPRB. Out of the 2 peers that are also analyzing SPRB, 0 agree with Gregory's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Gregory
- Jonathan Wolleben of "JMP Securities" Maintained at Buy and Held Target at $7 on, Friday, March 17th, 2023
- Tiago Fauth of "Credit Suisse" Reiterated at Buy and Held Target at $4 on, Friday, March 17th, 2023
Contributing Sources